Highlights of South West Immunotherapy Group Meeting - Next Session on June 4, 2025
Join the South West Immunotherapy Group (SWIG) for a comprehensive discussion on immunotherapy advancements, research updates, educational events, and initiatives to improve patient care. Featuring key topics such as REACT study, IO neurotoxicity, Melody-1 trial, access to biologics, subcutaneous IO treatments, and upcoming agenda items for the June 4, 2025 meeting in Taunton. Stay informed and engaged in cutting-edge immunotherapy developments to enhance patient outcomes across the region.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Highlights from the South West Immunotherapy Group (SWIG) Wednesday 20thNovember 2024 Next meeting: Wednesday 4thJune 2025, 13:00- 17:00, Taunton
FULL REPORT AVAILABLE ON REQUEST! Research: REACT:REmissioninduction of Arthritis caused by Cancer ImmunoTherapyis an NIHR funded randomised multicentre trial to guide initial therapy for checkpoint inhibitor (CPI) induced arthritis. The trial will compare standard treatment with steroids versus anti-TNF and is now open in RUH. IO Neurotoxicity study: Observational to determine incidence / outcomes MITRE: Immunotherapy and the microbiome link to less diverse microbiome and non- responders Melody-1: Adding oral MB097 alongside Pembroto see if can convert non-responder to responder IO in Primary Care: Standardised IO letter for Primary Care drafted by All Wales team to be shared for potential adoption across the SWIG region. Access to Biologics for IO induced colitis: SWIG is collating who has access to Infliximab and Vedolizumab and the number of cycles routinely given as there is currently variation across the region (UHBW & UHP).
Subcutaneous IO: SWIG aims to arrange for IO treatments to be administered in areas other than the chemotherapy day units wherever possible. Models for sub-cut IO are to be established in anticipation of an increase in agents being available. On the 4thJune 2025 agenda. Baseline cardiac testing: The Immuno-Oncology Clinical Network (IOCN) and British Cardio-Oncology Society have published a consensus statement to enable teams to get the necessary resources for baseline cardiac tests. A formal cardio-oncology pathway is being explored. IO education events: SWAG IO nursing team provided an education event for nurses which had 96 attendees. Peninsula team also hold regular education events. SWAG Cancer Alliance have been asked to fund future events in SWAG region. Bone Protection: IOCN are drafting bone protection guidance in line with SWIG recommendation to start as a default (as per osteoporosis society guidelines) at the same time that steroids commence and standardise patients who require bone density assessments / frequency. Vitamin D monitoring to be added to the initial IO order set.
On the agenda: Wednesday 4thJune 2025 Rheumatological Toxicity Management and update on REACT study Bi-specifics/ImmTACs/BiTEs Tumour infiltrating lymphocyte therapies Subcutaneous IO Cancer Vaccine Launch Pad Access to biologics IOCN updates (events/projects) Useful resource update IO Nurses Group Trainees.
